Surfing the MASH Tsunami

Surfing the MASH Tsunami

Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL

Denne podkasten er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(1073)

S3-E42 — Allied Health and Patient Empowerment for NAFLD

S3-E42 — Allied Health and Patient Empowerment for NAFLD

Send us Fan Mail Surfers Louise Campbell and Jörn Schattenberg are joined by patient advocate Robert Mitchell-Thain, liver nurse Michelle Clayton, and healthcare consultant Stephen Callaghan to talk a...

25 Aug 20221h 4min

S3-E41.6 - From the Vault: Why NASH Drug Trials Fail

S3-E41.6 - From the Vault: Why NASH Drug Trials Fail

Send us Fan Mail Jörn speaks about co-authoring an article, “The Nonalcoholic Steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future successes.” In doing so, he...

21 Aug 202217min

S3-E41.5 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

S3-E41.5 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

Send us Fan Mail THE NASH Tsunami audience came to know Jörn Schattenberg in the Fall of 2020 when he shared a paper he had recently co-authored on why NASH drug trials failed. This week, the same gro...

21 Aug 202212min

S3-E41.4 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

S3-E41.4 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

Send us Fan Mail THE NASH Tsunami audience came to know Jörn Schattenberg in the Fall of 2020 when he shared a paper he had recently co-authored on why NASH drug trials failed. This week, the same gro...

21 Aug 202212min

S3-E41.3 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

S3-E41.3 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

Send us Fan Mail THE NASH Tsunami audience came to know Jörn Schattenberg in the Fall of 2020 when he shared a paper he had recently co-authored on why NASH drug trials failed. This week, the same gro...

20 Aug 202212min

S3-E41.2 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

S3-E41.2 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

Send us Fan Mail THE NASH Tsunami audience came to know Jörn Schattenberg in the Fall of 2020 when he shared a paper he had recently co-authored on why NASH drug trials failed. This week, the same gro...

20 Aug 202213min

S3-E41.1 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

S3-E41.1 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

Send us Fan Mail THE NASH Tsunami audience came to know Jörn Schattenberg in the Fall of 2020 when he shared a paper he had recently co-authored on why NASH drug trials failed. This week, the same gro...

20 Aug 202212min

S3-E41- Improving NASH Clinical Trials By Reducing Screen Fail Rates

S3-E41- Improving NASH Clinical Trials By Reducing Screen Fail Rates

Send us Fan Mail THE NASH Tsunami audience came to know Jörn Schattenberg in the Fall of 2020 when he shared a paper he had recently co-authored on why NASH drug trials failed. This week, the same gro...

18 Aug 20221h 3min

Populært innen Vitenskap

fastlegen
tingenes-tilstand
rekommandert
liberal-halvtime
jss
sinnsyn
forskningno
dekodet-2
fjellsportpodden
villmarksliv
abels-tarn
rss-overskuddsliv
rss-nysgjerrige-norge
rss-paradigmepodden
rss-inn-til-kjernen-med-sunniva-rose
diagnose
tomprat-med-gunnar-tjomlid
rss-rekommandert
rss-lundqvist-podden
kvinnehelsepodden